Tumor expression of adiponectin receptor 2 and lethal prostate cancer
View/ Open
24474 bgv048.pdf (1.428Mb)
Access Status
Full text of the requested work is not available in DASH at this time ("restricted access"). For more information on restricted deposits, see our FAQ.Author
Rider, Jennifer
Fiorentino, Michelangelo
Kelly, Rachel
Gerke, Travis
Jordahl, Kristina
Sinnott, Jennifer
Giovannucci, Edward
Loda, Massimo
Mucci, Lorelei
Finn, Stephen
Published Version
https://doi.org/10.1093/carcin/bgv048Metadata
Show full item recordCitation
Rider, J. R., M. Fiorentino, R. Kelly, T. Gerke, K. Jordahl, J. A. Sinnott, E. L. Giovannucci, et al. 2015. “Tumor Expression of Adiponectin Receptor 2 and Lethal Prostate Cancer.” Carcinogenesis 36 (6): 639–47. https://doi.org/10.1093/carcin/bgv048.Abstract
To investigate the role of adiponectin receptor 2 (AdipoR2) in aggressive prostate cancer we used immunohistochemistry to characterize AdipoR2 protein expression in tumor tissue for 866 men with prostate cancer from the Physicians' Health Study and the Health Professionals Follow-up Study. AdipoR2 tumor expression was not associated with measures of obesity, pathological tumor stage or prostate-specific antigen (PSA) at diagnosis. However, AdipoR2 expression was positively associated with proliferation as measured by Ki-67 expression quartiles (P-trend < 0.0001), with expression of fatty acid synthase (P-trend = 0.001), and with two measures of angiogenesis (P-trend < 0.1). An inverse association was observed with apoptosis as assessed by the TUNEL assay (P-trend = 0.006). Using Cox proportional hazards regression and controlling for age at diagnosis, Gleason score, year of diagnosis category, cohort and baseline BMI, we identified a statistically significant trend for the association between quartile of AdipoR2 expression and lethal prostate cancer (P-trend = 0.02). The hazard ratio for lethal prostate cancer for the two highest quartiles, as compared to the two lowest quartiles, of AdipoR2 expression was 1.9 (95% confidence interval [CI]: 1.2-3.0). Results were similar when additionally controlling for categories of PSA at diagnosis and Ki-67 expression quartiles. These results strengthen the evidence for the role of AdipoR2 in prostate cancer progression.Citable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:41392159
Collections
- SPH Scholarly Articles [6354]
Contact administrator regarding this item (to report mistakes or request changes)